long intergenic non-protein coding RNA 2169Genealiases: []
Q-omics provides the consensus-scored LINC02169 profile across patient tissues and cancer cell-line models. LINC02169 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, LINC02169 is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, LINC02169 RNA expression shows 6,203 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight CHOL, BRCA, and STAD as cancer lineages where LINC02169 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02169 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02169 survival associations across molecular data types. LINC02169 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02169 RNA expression–survival associations across cancer types. High LINC02169 expression shows unfavorable associations in CHOL, READ, UCEC, LGG and THCA, but favorable associations in LUAD. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CHOL as the clearest survival context for LINC02169 RNA expression.
This table summarizes LINC02169 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02169. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02169 shows lower tumor expression in BRCA and higher tumor expression in KIRC. The BRCA box plot shows higher LINC02169 RNA expression in normal versus tumor tissue (log2 FC = −0.587, t-test p < 0.001).
This table shows molecular features associated with LINC02169 in patient tissues and cancer cell lines. In patient samples, LINC02169 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
